Trial Profile
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Rebif New Formulation (44 Microgram [Mcg] Three Times Weekly [Tiw] and 44 Mcg Once Weekly [ow]) in Subjects at High Risk of Converting to Multiple Sclerosis (REFLEX)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms REFLEX
- Sponsors Merck KGaA; Merck Serono
- 01 Apr 2023 Results of Post hoc analysis of baseline-to-24 month MRI data from patients with an FCDE , published in the Journal of Neurology
- 28 Oct 2022 Results of a post-hoc exploratory analysis assessing relationship between serum GDF-15 and disease stability in patients with a first clinical demyelinating event from this trial presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 01 Jul 2022 Results of post hoc analysis assessing effects of IFN beta-1a on spatio-temporal evolution of disease activity published in the European Journal of Neurology